

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2012342547 B2**

(54) Title
Method for producing substituted 5-fluoro-1H-pyrazolopyridines

(51) International Patent Classification(s)
C07D 471/04 (2006.01) **A61P 9/00** (2006.01)
A61K 31/506 (2006.01)

(21) Application No: **2012342547** (22) Date of Filing: **2012.11.21**

(87) WIPO No: **WO13/076168**

(30) Priority Data

(31) Number	(32) Date	(33) Country
11190789.5	2011.11.25	EP
11192301.7	2011.12.07	EP

(43) Publication Date: **2013.05.30**

(44) Accepted Journal Date: **2017.08.17**

(71) Applicant(s)
Adverio Pharma GmbH

(72) Inventor(s)
Fey, Peter; Grunenberg, Alfons; Bierer, Donald

(74) Agent / Attorney
Davies Collison Cave Pty Ltd, Level 14 255 Elizabeth Street, Sydney, NSW, 2000, AU

(56) Related Art
WO2011/147809
WO2012/028647
WO2003/095451
Yamanaka, H. et. al. Synlett, 1993, 1993(5), 353-354
Funabiki, K. et. al. Chem. Letters, 1994, 6, 1075-1078

(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES
PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG

(19) Weltorganisation für geistiges
Eigentum

Internationales Büro

(43) Internationales
Veröffentlichungsdatum
30. Mai 2013 (30.05.2013)



(10) Internationale Veröffentlichungsnummer
WO 2013/076168 A1

(51) Internationale Patentklassifikation:

C07D 471/04 (2006.01) **A61P 9/00** (2006.01)
A61K 31/506 (2006.01)

(21) Internationales Aktenzeichen: PCT/EP2012/073276

(22) Internationales Anmeldedatum:
21. November 2012 (21.11.2012)

(25) Einreichungssprache: Deutsch

(26) Veröffentlichungssprache: Deutsch

(30) Angaben zur Priorität:
11190789.5 25. November 2011 (25.11.2011) EP
11192301.7 7. Dezember 2011 (07.12.2011) EP

(71) Anmelder: **BAYER PHARMA**
AKTIENGESELLSCHAFT [DE/DE]; Müllerstr. 178,
13353 Berlin (DE). **BAYER INTELLECTUAL**
PROPERTY GMBH [DE/DE]; Alfred-Nobel-Str. 10,
40789 Monheim (DE).

(72) Erfinder: **FEY, Peter**; Am Eickhof 23, 42111 Wuppertal
(DE).

(74) Anwalt: **BAYER INTELLECTUAL PROPERTY**
GMBH; Alfred-Nobel-Str.10, 40789 Monheim (DE).

(81) Bestimmungsstaaten (soweit nicht anders angegeben, für
jede verfügbare nationale Schutzrechtsart): AE, AG, AL,
AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW,
BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK,
DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM,
GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Bestimmungsstaaten (soweit nicht anders angegeben, für
jede verfügbare regionale Schutzrechtsart): ARIPO (BW,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ,
TZ, UG, ZM, ZW), eurasisches (AM, AZ, BY, KG, KZ,
RU, TJ, TM), europäisches (AL, AT, BE, BG, CH, CY,
CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT,
LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Erklärungen gemäß Regel 4.17:

— hinsichtlich der Identität des Erfinders (Regel 4.17 Ziffer i)


[Fortsetzung auf der nächsten Seite]

(54) Title: METHOD FOR PRODUCING SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES

(54) Bezeichnung : VERFAHREN ZUR HERSTELLUNG VON SUBSTITUIERTEN 5-FLUOR-1H-PYRAZOLOPYRIDINEN



(VI)



(I),

(57) Abstract: The present application relates to a novel and efficient method for producing novel substituted 5-fluoro-1H-pyrazolopyridines of the formula (VI) which are suitable as an intermediate for producing medicaments and for producing medicaments for the treatment and/or prophylaxis of cardiovascular disorders. In particular, the 5-fluoro-1H-pyrazolopyridines of the formula (VI) are suitable for producing the compound of the formula (I) which serves for producing medicaments, for producing medicaments for the treatment and/or prophylaxis of cardiovascular disorders.

(57) Zusammenfassung:

[Fortsetzung auf der nächsten Seite]

**Veröffentlicht:**


— mit internationalem Recherchenbericht (Artikel 21 Absatz 3)

— vor Ablauf der für Änderungen der Ansprüche geltenden Frist; Veröffentlichung wird wiederholt, falls Änderungen eingehen (Regel 48 Absatz 2 Buchstabe h)

Die vorliegende Anmeldung betrifft ein neues und effizientes Verfahren zur Herstellung von neuen substituierten 5-Fluor-1H-pyrazolopyridinen der Formel (VI), welche sich als Zwischenstufe zur Herstellung von Arzneimitteln und zur Herstellung von Arzneimitteln zur Behandlung und/oder Prophylaxe von kardiovaskulären Erkrankungen eignen. Insbesondere eignen sich die 5-Fluor-1H-pyrazolopyridine der Formel (VI) zur Herstellung der Verbindung der Formel (I), welche zur Herstellung von Arzneimitteln, zur Herstellung von Arzneimitteln zur Behandlung und/oder Prophylaxe von kardiovaskulären Erkrankungen, dient.


Method for producing substituted 5-fluoro-1H-pyrazolopyridines

The present application relates to a novel and efficient process for preparing novel substituted 5-fluoro-1H-pyrazolopyridines of the formula (VI)



- 5 which serves as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders.

More particularly, the 5-fluoro-1H-pyrazolopyridines of the formula (VI) are suitable for preparation of compound of the formula (I)



- 10 which serves for production of medicaments and for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders.

The compound of the formula (I) acts as a stimulator of soluble guanylate cyclase and can be used as an agent for prophylaxis and/or treatment of cardiovascular disorders, for example for treatment of hypertension and heart failure, stable and unstable angina pectoris, peripheral and cardiac vascular disorders, of arrhythmias, for treatment of thromboembolic disorders and ischaemias such as myocardial infarction, stroke, transitory and ischaemic attacks, peripheral perfusion disorders,

15

prevention of restenoses such as after thrombosis therapy, percutaneous transluminal angioplasty (PTA), percutaneous transluminal coronary angioplasty (PTCA), bypass, and for treatment of arteriosclerosis, asthmatic disorders and diseases of the urogenital system, for example prostate hypertrophy, erectile dysfunction, female sexual dysfunction, osteoporosis, glaucoma, pulmonary hypertension, gastroparesis, scleroderma and incontinence.

The compound of the formula (I) may be present in various crystal forms and solvates. The compound of the formula (I) exists in five polymorphs with melting points 257°C (polymorph I), 253°C (polymorph II), 247°C (polymorph III), 246°C (polymorph IV), 234°C (polymorph V), a dimethylformamide/water solvate (DMF content 13.6%, water content 0.9%), a di-dimethyl sulphoxide solvate (stoichiometric value: 26.8% DMSO), a triacetic acid solvate (29.7% acetate), a monohydrate (4.1% water) and a dihydrate (7.8% water). The prior art, WO 2011/147809, describes the compound of the formula (I) in Example 1 as a substance.


The crystal polymorph of the compound formula (I) in polymorph (I) is notable for stability and particularly for the fact that it is stable even in the micronization process and thus no conversion and recrystallization takes place.

The di-dimethyl sulphoxide solvate of the compound of the formula (I) has the advantage of much better filterability than the substance in the prior art. Furthermore, the preparation process via the di-dimethyl sulphoxide solvate of the compound of the formula (I) leads to a very high purity of the compound of the formula (I).

WO 03/095451, WO 2011/064156 and WO 2011/064171 disclose the synthesis of pyrazolopyridines unsubstituted on the pyridine ring. In these disclosures, the bicyclic ring system is built up by reaction of phenylbenzyl hydrazine with ethyl cyanopyruvate. This synthesis method is unsuitable for the formation of 5-fluoro-1H-pyrazolopyridines.

WO 2009/018415 describes the synthesis of 5-fluoro-1H-pyrazolo[3,4-b]pyridine-3-amine E. Selective dechlorination of the nicotinic acid A to give the compound B, subsequent conversion to the amide C, the reduction thereof to the nitrile and the final cyclization with hydrazine hydrate form the 5-fluoro-1H-pyrazolo[3,4-b]pyridine core. Scheme 1 below illustrates the synthesis.


Scheme 1:



[i) $\text{Pd}(\text{OAc})_2$, PPh_3 , NEt_3 , HCO_2H ; ii) 1) $(\text{COCl})_2$, CH_2Cl_2 , cat. DMF, 2) NH_3 (g), dioxane, iii) TFAA, NEt_3 ; iv) $\text{H}_2\text{NNH}_2 \times \text{H}_2\text{O}$, n-BuOH].

- 5 A disadvantage of this process is that, proceeding from 5-fluoro-1H-pyrazolo[3,4-b]pyridine E, further steps such as the diazotization reaction and conversion to the iodo compound, followed by an alkylation with a benzyl derivative and subsequent functionalization for introduction of the cyano group are required in order to obtain the desired 5-fluoro-1H-pyrazolopyridines of the formula (VI). This is illustrated by way of example in Scheme 2.

10 Scheme 2:




A further disadvantage is that the diazotization is conducted under anhydrous conditions and the diazonium salt has to be isolated, which necessitates considerable safety precautions on conversion to the industrial scale and thus causes high production costs.

- 15 A further disadvantage is that the alkylation with a benzyl derivative proceeds unselectively and the product is obtained in only a low yield after complex purification and separation of the isomers.


A further disadvantage is that, in the course of cyanation, toxic copper cyanide has to be handled, which necessitates additional safety precautions in the preparation and in the disposal of mother liquors and aqueous phases, and thus causes high production costs.

- 5 A further disadvantage is that the preparation of 5-fluoro-1H-pyrazolopyridines of the formula (VI), according to the process described in Scheme 1, entails the preparation and purification of seven intermediates and affords only a small overall yield.


10 According to a first aspect the present invention provides a process for preparing a compound of the formula (VI)



wherein the compound of the formula (V)



is prepared by reaction of an ester of the formula (IVa)




in which

T^1 is (C_1-C_4) -alkyl,


with formamide.

5

According to a second aspect the present invention provides a process for preparing a compound of the formula (I)



wherein a compound of the formula (VI)




10

is used,

wherein the compound of formula (VI) is prepared by a process as defined in the first aspect and the resulting compound of the formula (I) is optionally converted, with one or more appropriate (i) solvents and/or (ii) acids or bases, to a solvate, salt or solvate of a salt thereof.


According to a third aspect the present invention provides a process for preparing a compound of the formula (I), wherein a compound of the formula (VI)



5 is used,

wherein the compound of formula (VI) is prepared by a process as defined in the first aspect and the resulting compound of the formula (I) is optionally converted, with one or more appropriate (i) solvents and/or (ii) acids or bases, to a solvate, salt or solvate of a salt thereof.

10 According to a fourth aspect the present invention provides a process for preparing a compound of the formula (I), wherein a compound of the formula (VI)




is used,

15 wherein the compound of formula (VI) is prepared by a process as defined in the first aspect and the resulting compound of the formula (I) is optionally converted, with one or more appropriate (i) solvents and/or (ii) acids or bases, to a solvate, salt or solvate of a salt thereof.


20 According to a fifth aspect the present invention provides a process for preparing a compound of the formula (I), wherein a compound of the formula (VI) is used, this being prepared according to the first aspect by converting the compound of the formula (VI) to the compound of the formula (VII)

- 4C -




x HCl (VII),

subsequently reacting the compound of the formula (VII) in an inert solvent in the presence of a suitable base with a compound of the formula (VIIIa)



(VIIIa)


5 to give the compound of the formula (VIII)



(VIII),


and then reducing the compound of the formula (VIII) in an inert solvent in the presence of a suitable reducing agent to give the compound (IX)

- 4D -




and thereafter reacting the compound of the formula (IX) with methyl chloroformate or with dimethyl dicarbonate in the presence of a suitable base, with or without solvent, to give the compound of the formula (I), and optionally converting the resulting compound of the formula (I) with one or more appropriate (i) solvents and/or (ii) acids or bases, to a solvate, salt or solvate of a salt thereof.

According to a sixth aspect the present invention provides a compound of the formula (I) in crystalline form of polymorph I



wherein the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 5.9, 6.9 and 22.7.

According to a seventh aspect the present invention provides a compound of the formula (I) in crystalline form of polymorph I



wherein the IR spectrum of the compound exhibits band maxima at 1707, 1633 and 1475 cm^{-1} .

According to an eighth aspect the present invention provides a process for preparing a compound of the formula (I) in crystalline form of polymorph I, wherein the compound of the formula (I), present in one or more polymorphs or as a solvate in an inert solvent, is stirred at a temperature in the range of 20°C - 120°C and the compound of the formula (I) is isolated as crystalline polymorph I.

According to a ninth aspect the present invention provides a compound according to the sixth or seventh aspects for the treatment of a disorder.

15


According to a tenth aspect the present invention provides a medicament comprising a compound according to the sixth or seventh aspects and no greater proportions of any other form of the compound of the formula (I).

20 According to an eleventh aspect the present invention provides a medicament comprising a compound according to the sixth or seventh aspects in more than 90 per cent by weight based on the total amount of the compound of the formula (I) present.

According to a twelfth aspect the present invention provides a use of a compound according to the sixth or seventh aspects in the manufacture of a medicament for the treatment of a cardiovascular disorder.

- 5 According to a thirteenth aspect the present invention provides a method for the treatment of a cardiovascular disorder, the method comprising administering an effective amount of a compound according to the sixth or seventh aspects.

- 10 According to a fourteenth aspect the present invention provides a crystalline substance compound of the formula (I) in the form of the di-dimethyl sulphoxide solvate,




wherein the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 18.8, 20.3 and 21.7.

- 15 According to a fifteenth aspect the present invention provides a crystalline substance compound of the formula (I) in the form of the di-dimethyl sulphoxide solvate,


2012342547 03 Jul 2017

- 4G -



wherein the IR spectrum of the compound exhibits band maxima at 1720, 1628 and 1481 cm^{-1} .

- According to a sixteenth aspect the present invention provides a process for preparing a compound of the formula (I) as the di-dimethyl sulphoxide solvate in crystalline form, wherein the compound of the formula (I), present in one or more polymorphs or as a solvate in dimethyl sulphoxide, or a mixture of dimethyl sulphoxide and an inert solvent, is stirred at a temperature in the range of 20 - 120°C and the di-dimethyl sulphoxide solvate is isolated.
- The present invention seeks to provide an efficient process with high yield for preparation of 5-fluoro-1H-pyrazolopyridines of the formula (VI)




- as a key component for an efficient process with high yield for preparation of compound of the formula (I)



(I)

- 5 This may be achieved in accordance with the present invention, as follows. Scheme 3 below illustrates the individual reaction steps by way of example.


Scheme 3:



- 6 -

[a): LiCl, MeSO₃H, EtOH; b) formamide, NaOMe/MeOH, EtOH; c) POCl₃, CH₃CN, sulpholane; d) 1. NaOMe/MeOH, 2. NH₄Cl/EtOH; e) DMF, NEt₃, phenylazomalononitrile; f) Pd/C, H₂, DMF; g) iPrOH, methyl chloroformate, NEt₃].

Step a) is already known for the unsubstituted pyrazolopyridines through (WO 03/004503 (Example IIIb) and WO 03/095451 (Example 2A)):



[aa): CF₃SO₃H, reflux for 3 days, chromatography, 49.9% yield].

Compared to the prior art (WO 03/004503, Example IIIb and WO 03/095451, Example 2A), the preparation of IV proceeds with a much higher yield.

10 A further advantage is that, rather than the corrosive trifluoroacetic acid, ethanol, which is much less expensive, is used as the solvent.

A further advantage is that the reaction time is considerably shorter compared to the prior art.


A further advantage is that the preparation of IV proceeds with high selectivity and the product is formed in high purity without significant by-product formation, and no complex purification
15 procedures are required.

A further advantage is that IV is obtained by crystallization in high yield and purity.


Steps d) – g) are already known for the unsubstituted pyrazolopyridines through WO 03/095451, WO 2011/064156 and WO 2011/064171 and can be used analogously.

Specifically, the process according to the invention for preparing a compound of the formula (VI)
20 comprises

- 7 -




which by the cyclization of the 5-aminopyrazole derivative (IIa)




in which

5 T^1 is (C_1-C_4) -alkyl,

in the presence of a suitable acid with the aldehyde (III)




in which R^1 and R^2 are each independently methyl, ethyl, isopropyl, phenyl or, together with the nitrogen atom to which they are bonded, are




to give the ester of the formula (IVa)

- 8 -




in which T¹ is as defined above,

the subsequent reaction thereof with ammonia or formamide to give the amide of the formula (V)




5 and the subsequent dehydration to give the nitrile (VI).

The present invention further provides for the use of the compound of the formula (VI)




for preparation of the compound of the formula (I)

- 9 -




and the *N*-oxides, salts, solvates, salts of *N*-oxides and solvates of the *N*-oxides and salts thereof.


The present invention further provides for the use of the compound of the formula (III)



- 5 in which R¹ and R² are each independently methyl, ethyl, isopropyl, phenyl or, together with the nitrogen atom to which they are bonded, are




for preparation of the compound of the formula (I)




and the *N*-oxides, salts, solvates, salts of *N*-oxides and solvates of the *N*-oxides and salts thereof.

The present invention further provides for the use of the compound of the formula (VI) for
 5 preparation of the compound of the formula (I) as specified above, wherein the compound of the
 formula (VI) is converted to the compound of the formula (VII)




the latter is subsequently reacted in an inert solvent in the presence of a suitable base with
 the compound of the formula (VIIIa)

- 11 -




(VIIIa)

to give the compound of the formula (VIII)



(VIII),


and then the latter is reduced in an inert solvent in the presence of a suitable reducing agent
5 to give the compound (IX)



(IX),

- 12 -

then the latter is reacted in the presence of a suitable base in the presence or absence of a solvent with methyl chloroformate or with dimethyl dicarbonate to give the compound of the formula (I)



5

and optionally the resulting compound of the formula (I) is optionally converted with the appropriate (i) solvents and/or (ii) acids or bases to the solvates, salts and/or solvates of the salts thereof.

The conversion (VI) → (VII) is effected by methods known to those skilled in the art in a two-stage process, first to form the imino ester with sodium methoxide in methanol at 0°C to +40°C and then nucleophilic addition of one ammonia equivalent, for example ammonia or ammonium chloride, in acetic acid or an alcohol to form the amidine (VII) at +50 to +150°C.

Suitable alcohols for the conversion (VI) → (VII) are alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol.

Inert solvents for the process step (VII) + (VIIIa) → (VIII) are alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or mineral oil fractions, or other solvents such as dimethylformamide (DMF), dimethyl sulphoxide (DMSO), sulpholane, *N,N'*-dimethylpropyleneurea (DMPU), *N*-methylpyrrolidone (NMP), pyridine, acetonitrile or else water. It is likewise possible to use mixtures of the solvents mentioned. Preference is given to DMF and sulpholane.

Suitable bases for the process step (VII) + (VIIIa) $\rightarrow$ (VIII) are alkali metal hydroxides, for example lithium hydroxide, sodium hydroxide or potassium hydroxide, alkali metal carbonates such as lithium carbonate, sodium carbonate, potassium carbonate or caesium carbonate, alkali metal hydrogencarbonates such as sodium hydrogencarbonate or potassium hydrogencarbonate, 5 alkali metal alkoxides such as sodium methoxide or potassium methoxide, sodium ethoxide or potassium ethoxide or potassium tert-butoxide, or organic amines such as triethylamine, diisopropylethylamine, pyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or 1,5-diazabicyclo[4.3.0]non-5-ene (DBN). Preference is given to triethylamine.

10 The reaction (VII) + (VIIIa) $\rightarrow$ (VIII) is generally conducted within a temperature range of +20°C to +150°C, preferably at +80°C to +120°C, optionally in a microwave. The conversion can be effected at standard, elevated or reduced pressure (for example from 0.5 to 5 bar). In general, standard pressure is employed.

The compound of the formula (VIIIa) can be prepared analogously to the literature L. F. Cavalieri, J. F. Tanker, A. Bendich, J. Am. Chem. Soc., 1949, 71, 533.

15 The reductions (VIII) $\rightarrow$ (IX) are effected in the presence of a suitable catalyst in an inert solvent within a temperature range of +20°C to +100°C under hydrogen pressure (for example from 1 to 100 bar). Preference is given to a temperature range of 40°C to 80°C and a hydrogen pressure range of 5 to 70 bar.

20 Inert solvents for the reduction (VIII) $\rightarrow$ (IX) are, for example, alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, or other solvents such as dimethylformamide (DMF), dimethyl sulphoxide (DMSO), *N,N'*-dimethylpropyleneurea (DMPU), *N*-methylpyrrolidone (NMP), pyridine, acetonitrile or else water. It is likewise possible to use mixtures of the solvents mentioned. Preference is given to DMF and pyridine.

25 Suitable catalysts for the conversion (VIII) $\rightarrow$ (IX) are, for example, palladium on activated carbon, platinum on carbon, palladium hydroxide or Raney nickel.

The reduction (VIII) $\rightarrow$ (IX) can alternatively be effected with a metal or metal salt, for example iron, zinc or tin(II) chloride in a suitable acid, for example hydrogen chloride/hydrochloric acid, sulphuric acid, phosphoric acid or acetic acid, within a temperature range of +20°C to +140°C.

30 Inert solvents for process step (IX) $\rightarrow$ (I) are, for example, alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, ethers such as diethyl ether, diisopropyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, halogenated hydrocarbons such as dichloromethane, trichloromethane, carbon tetrachloride, trichloroethylene or

chlorobenzene, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or mineral oil fractions, or other solvents such as dimethylformamide (DMF), dimethyl sulfoxide (DMSO), *N,N'*-dimethylpropyleneurea (DMPU), *N*-methylpyrrolidone (NMP), acetonitrile, ethyl acetate or else water. It is likewise possible to use mixtures of the solvents mentioned. Preference is given to
5 isopropanol and tetrahydrofuran, and to a mixture of isopropanol and tetrahydrofuran.


Suitable bases for the process step (IX) $\rightarrow$ (I) are alkali metal hydrides such as sodium hydride, alkali metal hydroxides, for example lithium hydroxide, sodium hydroxide or potassium hydroxide, alkali metal carbonates such as lithium carbonate, sodium carbonate, potassium carbonate or caesium carbonate, alkali metal hydrogencarbonates such as sodium hydrogencarbonate or
10 potassium hydrogencarbonate, alkali metal alkoxides such as sodium methoxide or potassium methoxide, sodium ethoxide or potassium ethoxide or potassium *tert*-butoxide, or organic amines such as triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or 1,5-diazabicyclo[4.3.0]non-5-ene (DBN). Preference is given to triethylamine.

15 The reaction (IX) $\rightarrow$ (I) is generally conducted within a temperature range of -10°C to +70°C, preferably at 0°C to +50°C. The conversion can be effected at standard, elevated or reduced pressure (for example from 0.5 to 5 bar). In general, standard pressure is employed.

Compounds of the formula (IIa) are known from the literature and can be prepared in analogy to Example 20A in WO 00/06569.

20 Compounds of the formula (III) are known from the literature H. Yamanaka, S. Yamashita and T. Ishihara, Synlett 353-354 (1993). The synthesis disclosed therein is illustrated in Scheme 4.

Scheme 4:



[k] 3 eq dimethylbenzylamine, 130 – 140°C; l) 10 eq CH₃I, reflux, m) 1M NaOH, 20°C; n) DMSO-
 5 H₂O (1:1), morpholine, 40°C, 3h].


A disadvantage of this process is that, in the preparation of (XVIb), according to H. Yamanaka, M. Kuwabara, M. Okudo, K. Fukunishi and M. Nomura, *Nippon Kagaku Kaishi* (10) 1988-1994 (1985), only a yield of 66% is achieved and, in this process, very large amounts (2.79 kg per kg of (XVIb)) of by-product (dimethyldibenzyl nitrobenzenesulphonate) are obtained, which have to be
 10 removed and disposed of.

A further disadvantage of this process is that, according to H. Yamanaka, H. Ganbayashi, M. Kuwabara, K. Fukunishi and M. Nomura, *Nippon Kagaku Kaishi* (7) 1036-1043 (1988), proceeding from (XVIb), the alkylation requires 10 equivalents of the carcinogenic alkylating agent methyl iodide.

15 A further disadvantage of this process is that, according to H. Yamanaka, S. Yamashita and T. Ishihara, *Synlett* 353-354 (1993), the reaction of O with morpholine forms not only the desired product (IIIb) but also 11% of the by-product (IIIa), which necessitates a complex purification, the result being that the overall synthesis for preparation of (IIIb) gives only a low overall yield and causes high production costs.

The synthesis described therein, however, is unsuitable for the preparation of the aldehydes of the formula (III) on the industrial scale, and so a new and efficient synthesis has been developed, which is illustrated by way of example in Scheme 5.

5 Scheme 5:




[o) without solvent; p) dichloromethane or without solvent, morpholine; q) without solvent, methyl methanesulphonate; r) NaOH, water; s) morpholine/triethylamine.]

- 10 The compound of the formula (XIII) is known according to the literature Markovskii, L. N.; Kolesnik, N. P.; Shermolovich, Yu. G Zhurnal Obshchei Khimii (1980), 50(4), 826-829. The synthesis disclosed therein is illustrated in Scheme 6.

- 18 -


in which R¹ and R² are each as defined above

and with methyl methanesulphonate to give a compound of the formula (XIVa)



in which R¹ and R² are each as defined above


5 and with sodium hydroxide to give a compound of the formula (XVa)




in which R¹ and R² are each as defined above

and finally converted under basic conditions to give the compound of the formula (III).


The present invention further preferentially provides a process for preparing compounds of the
10 formula (IIIa)




wherein trifluoromethanesulphonic anhydride of the formula (X) is reacted with 2,2,3,3-tetrafluoro-1-propanol of the formula (XI) without solvent and the resulting 2,2,3,3-tetrafluoropropyl trifluoromethanesulphonate of the formula (XII) is reacted with morpholine to give a compound of
15 the formula (XIII)



and with methyl methanesulphonate to give a compound of the formula (XIV)



and with sodium hydroxide to give a compound of the formula (XV)



- 5 and finally with addition of morpholine to give the compound of the formula (III).

The new synthesis has the advantage over the prior art that the intermediate (XII) and the intermediates (XIV) and (XV) unknown to date need not be isolated, which greatly reduces the industrial complexity of the synthesis.

- 10 The yields of the resulting aldehydes of the formula (III) are much higher with the new synthesis process than in the prior art.

"Basic conditions" in the context of the invention for the process step (XIVa) to (XVa) means that the acid formed in the reaction is scavenged by auxiliary bases, for example sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, or triethylamine to form the corresponding salts.

- 15 Compared to the prior art, the preparation of (XIII) proceeds with a much higher yield. It is advantageous that no solvent is required for preparation of (XII), and that the intermediate XII is used without further purification in the subsequent stage to give (XIII).

- 20 A further advantage of this process is that no significant wastes are formed in the preparation of (XIII). It is also advantageous that the trifluoromethanesulphonic acid and morpholine can be recovered from the morpholinium trifluoromethanesulphonate formed.

Compared to the prior art, the preparation of (XIV) requires only one equivalent of the alkylating agent. The reaction is conducted without solvent and proceeds virtually quantitatively, which achieves a high space-time yield.

A further advantage of this process is that the product (XIV) is not isolated, (XIV) is dissolved in water and this solution is reacted with sodium hydroxide solution to give (XV).

A further advantage of this process is that the product (XV) is also not isolated; reaction of the aqueous solution with morpholine affords (IIIa) as the sole product in high yield.

- 5 A further advantage of this process is that (IIIa) is obtained in high overall yield and purity by crystallization.

The cyclization of the 5-aminopyrazole derivative of the compound (IIa) with the aldehyde of the compound (III) to give the compound of the formula (IV) is effected in an inert solvent, optionally in the presence of an acid and optionally of an alkali metal salt, within a temperature range of
10 +10°C to +200°C, preferably at +20°C to +100°C, at standard pressure, within, for example 2 to 50 hours, preferably within 2 to 20 hours.

Acids are, for example, hydrochloric acid, trifluoroacetic acid and methanesulphonic acid. Preference is given to methanesulphonic acid and hydrochloric acid.

Alkali metal salts are sodium chloride or lithium chloride. A preferred alkali metal salt is lithium
15 chloride.

Inert solvents are, for example, alcohols such as methanol, ethanol, n-propanol or *iso*-propanol, n-butanol, ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or mineral oil fractions or other solvents, acetonitrile or *N,N*-dimethylformamide, or mixtures of
20 solvents. Preference is given to ethanol, diethylene glycol dimethyl ether or dioxane.

The preferred formation of the amide (IVa) → (V) is effected by reaction in an inert solvent with formamide in the presence of a base within a temperature range of 0°C to + 150°C, preferably of +20°C to +130°C, at standard pressure or elevated pressure, within 2 to 24 hours.

Inert solvents are, for example, alcohols such as methanol, ethanol, n-propanol or *iso*-propanol.
25 Preference is given to ethanol.

Suitable bases for the preferred process step (IVa) → (V) are alkali metal carbonates such as lithium carbonate, sodium carbonate, potassium carbonate or caesium carbonate, alkali metal hydrogencarbonates such as sodium hydrogencarbonate or potassium hydrogencarbonate, alkali metal alkoxides such as sodium methoxide or potassium methoxide, sodium ethoxide or potassium
30 ethoxide or potassium *tert*-butoxide, or organic amines such as triethylamine, diisopropylethylamine, pyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or 1,5-

diazabicyclo[4.3.0]non-5-ene (DBN). Preference is given to sodium methoxide and sodium ethoxide.

The formation of the amide (IVa) → (V) is alternatively effected by reaction with ammonia within a temperature range of 0°C to + 50°C, preferably of +20°C to +30°C, at standard pressure or
5 elevated pressure, within 24 to 72 hours.

Inert solvents are, for example, alcohols such as methanol, ethanol, n-propanol or *iso*-propanol. Preference is given to using a solution of ammonia in methanol in a concentration of 5N to 7N.

The dehydration of the amide (V) to the nitrile (VI) is effected in an inert solvent, optionally in the presence of a suitable base, with a suitable dehydrating agent, for example phosphorus oxychloride,
10 trifluoroacetic anhydride, acetic anhydride or trifluoromethanesulphonic anhydride, within a temperature range of 0°C to +150°C, preferably at +50°C to +110°C, within 1 to 12 hours.

Preference is given to phosphorus oxychloride.

Inert solvents are ethers such as diethyl ether, dioxane, tetrahydrofuran (THF), glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons such as benzene, toluene, xylene, hexane,
15 cyclohexane or mineral oil fractions or other solvents, pyridine, sulpholane, acetonitrile or *N,N*-dimethylformamide, or mixtures of solvents. Preference is given to sulpholane and acetonitrile.

Suitable bases are, for example, organic amines such as triethylamine, diisopropylethylamine, pyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or 1,5-diazabicyclo[4.3.0]non-5-ene (DBN). Preference is given to pyridine.

20 The compounds described in the context of the process according to the invention may also be in the form of the salts, solvates or solvates of the salts thereof.

The compounds described in the context of the process according to the invention may, depending on the structure, also be in the form of the tautomers thereof.

Preferred salts in the context of the invention are physiologically acceptable salts of the
25 compounds used and prepared in the process according to the invention.

Physiologically acceptable salts of the compounds used and prepared in the process according to the invention include acid addition salts of mineral acids, carboxylic acids and sulphonic acids, for example salts of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid,
30 naphthalenedisulphonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid.

Physiologically acceptable salts of the compounds used and prepared in the process according to the invention also include salts of customary bases, by way of example and with preference alkali metal salts (e.g. sodium and potassium salts), alkaline earth metal salts (e.g. calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines having 1 to 16
5 carbon atoms, by way of example and with preference ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, dihydroabiethylamine, arginine, lysine, ethylenediamine and methylpiperidine.


In the context of the invention, solvates refer to those forms of the compounds used and prepared
10 in the process according to the invention which, in the solid or liquid state, form a complex by coordination with solvent molecules. Hydrates are a specific form of the solvates in which the coordination is with water.

In the context of the present invention, the substituents, unless specified otherwise, are each defined as follows:


15 Alkyl in the context of the invention is a linear or branched alkyl radical having 1 to 4 carbon atoms. Preferred examples include: methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, *iso*-butyl, *sec*-butyl and *tert*-butyl.

The present invention is illustrated in detail below by non-limiting preferred examples and comparative examples. Unless stated otherwise, all amounts given refer to percentages by weight.


The present invention provides a process for preparing compounds of the formula (VI)



characterized in that the compound of the formula (V)



5 is prepared by reaction of an ester of the formula (IVa)




in which

T¹ is (C₁-C₄)-alkyl

with formamide.

10 The present invention further provides a process as described above, characterized in that an ester of the formula (IVa) is prepared by cyclization of the 5-aminopyrazole derivative (IIa)


- 24 -




in which

T¹ is (C₁-C₄)-alkyl


in the presence of an acid and an alkali metal salt with an aldehyde of the formula (III)



in which R¹ and R² are each independently methyl, ethyl, isopropyl, phenyl or, together with the nitrogen atom to which they are bonded, are




- 10 The present invention further provides a process as described above, characterized in that the aldehyde used in the cyclization reaction is the compound of the formula (IIIa)




The present invention further provides a process for preparing aldehydes of the formula (III)

- 25 -




in which R^1 and R^2 are each independently methyl, ethyl, isopropyl, phenyl or, together with the nitrogen atom to which they are bonded, are




5

characterized in that trifluoromethanesulphonic anhydride is reacted with 2,2,3,3-tetrafluoro-1-propanol without solvent and the resulting 2,2,3,3-tetrafluoropropyl trifluoromethanesulphonate is reacted with a compound of the formula (XIIa)




10 in which R^1 and R^2 are each as defined above, to give a compound of the formula (XIIIa)



in which R^1 and R^2 are each as defined above


and with methyl methanesulphonate to give a compound of the formula (XIVa)



15 in which R^1 and R^2 are each as defined above

and with sodium hydroxide to give a compound of the formula (XVa)


- 26 -




in which R^1 and R^2 are each as defined above

and finally converted under basic conditions to give the compound of the formula (III).


The present invention further provides a process for preparing compounds of the formula (IIIa)



wherein trifluoromethanesulphonic anhydride of the formula (X) is reacted with 2,2,3,3-tetrafluoro-1-propanol of the formula (XI) without solvent and the resulting 2,2,3,3-tetrafluoropropyl trifluoromethanesulphonate of the formula (XII) is reacted with morpholine to give a compound of the formula (XIII)




and with methyl methanesulphonate to give a compound of the formula (XIV)




and with sodium hydroxide to give a compound of the formula (XV)

- 27 -




and finally with addition of morpholine to give the compound of the formula (IIIa).

The present invention further provides a process for preparing the compound of the formula (I)




characterized in that compounds of the formula (VI)



are used,

these being characterized in that they are prepared by the process specified above and the resulting
5 compounds of the formula (I) are optionally converted with the appropriate (i) solvents and/or (ii) acids or bases to the solvates, salts and/or solvates of the salts thereof.

The present invention further provides a process for preparing the compound of the formula (I), characterized in that compounds of the formula (VI)




10 are used,

these being characterized in that they are prepared by the processes specified above and the resulting compounds of the formula (I) are optionally converted with the appropriate (i) solvents and/or (ii) acids or bases to the solvates, salts and/or solvates of the salts thereof.

The present invention further provides a process for preparing the compound of the formula (I),
15 characterized in that compounds of the formula (VI)


- 29 -




are used,

these being characterized in that they are prepared by the processes specified above and the resulting compounds of the formula (I) are optionally converted with the appropriate (i) solvents
5 and/or (ii) acids or bases to the solvates, salts and/or solvates of the salts thereof.

The present invention further provides a process for preparing compound (I), characterized in that the compound of the formula (VI) is used, this being prepared by the processes specified above, by converting the compound of the formula (VI) to the compound of the formula (VII)




10 subsequently reacting the latter in an inert solvent in the presence of a suitable base with the compound of the formula (VIIIa)




to give the compound of the formula (VIII)

- 30 -



and then reducing the latter in an inert solvent in the presence of a suitable reducing agent to give the compound (IX)




- 5 and thereafter reacting the latter with methyl chloroformate or with dimethyl dicarbonate in the presence of a suitable base with or without solvent to give the compound of the formula (I), and optionally converting the resulting compounds of the formula (I) with the appropriate (i) solvents and/or (ii) acids or bases to the solvates, salts and/or solvates of the salts thereof.

The present invention further provides the compound of the formula (I) in crystalline form of polymorph I

10


- 31 -



characterized in that the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 5.9, 6.9, 22.7.

The present invention further provides the compound of the formula (I) in polymorph (I) as described above, characterized in that the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 5.9, 6.9, 16.2, 16.5, 24.1, 22.7, 24.7.

The present invention further provides the compound of the formula (I) in crystalline form of polymorph I



characterized in that the IR spectrum of the compound exhibits band maxima at 1707, 1633, 1475 cm^{-1} .

Compound of the formula (I) in polymorph (I) as described above, characterized in that the IR spectrum of the compound exhibits band maxima at 1707, 1633, 1566, 1475, 1255, 1223 cm^{-1} .

5 The invention further provides a process for preparing the compound of the formula (I) in crystalline form of polymorph I, characterized in that the compound of the formula (I), present in one or more polymorphs or as a solvate in an inert solvent, is stirred at a temperature of 20°C - 120°C and the compound of the formula (I) is isolated in crystalline polymorph I.

Preferred solvents for the process for preparing the compound of the formula (I) in crystalline form
10 of polymorph I are a mixture of ethyl acetate/ethanol/water, isopropanol, a mixture of isopropanol/water, methanol, a mixture of methanol/water, acetonitrile, acetone, tetrahydrofuran and methyl tert-butyl ether.

A preferred temperature range for the process for preparing the compound of the formula (I) in crystalline form of polymorph I is from 20°C to 90°C.

15

The present invention further provides a compound of the formula (I) in polymorph (I) as described above for treatment of disorders.


The present invention further provides a medicament comprising a compound of the formula (I) in polymorph (I) as described above and no greater proportions of any other form of the compound of the
20 formula (I) in polymorph (I) as described above. Medicament comprising a compound of the formula (I) in polymorph (I) as described above in more than 90 per cent by weight based on the total amount of the compound of the formula (I) present in polymorph (I) as described above.

The present invention further provides for the use of the compound of the formula (I) in polymorph (I) as described above for production of a medicament for treatment of cardiovascular
25 disorders.

The present invention further provides the method for treatment of cardiovascular disorders by administering an effective amount of a compound of the formula (I) in polymorph (I) as described above.

The present invention further provides the compound of the formula (I) as the di-dimethyl
30 sulphoxide solvate


- 33 -



characterized in that the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 18.8, 20.3, 21.7.

- 5 The present invention further provides the compound of the formula (I) as the di-dimethyl sulphoxide solvate, characterized in that the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 12.0, 16.6, 17.8, 18.8, 20.3, 21.7.

The present invention further provides the compound of the formula (I) as the di-dimethyl sulphoxide solvate




characterized in that the IR spectrum of the compound exhibits band maxima at 1720, 1628, 1481 cm^{-1} .

The present invention further provides the compound of the formula (I) as the di-dimethyl sulphoxide solvate, characterized in that the IR spectrum of the compound exhibits band maxima at 1720, 1628, 1481, 1234, 1041, 1017 cm^{-1} .


- 5 The present invention further provides a process for preparing the compound of the formula (I) as the di-dimethyl sulphoxide solvate in crystalline form, characterized in that the compound of the formula (I), present in one or more polymorphs or as a solvate in dimethyl sulphoxide or a mixture of dimethyl sulphoxide and an inert solvent, for example ethyl acetate, is stirred at a temperature of 20 - 120°C and the di-dimethyl sulphoxide solvate is isolated. Preference is given to a temperature
- 10 range of 20 to 90°C.

The present invention further provides the compound of the formula (XIV)



and the salts, solvates and solvates of the salts thereof.

The present invention further provides the compound of the formula (XV)



15

and the salts, solvates and solvates of the salts thereof.

A. Examples**Abbreviations:**

Ac	acetyl
CI	chemical ionization (in MS)
DCI	direct chemical ionization (in MS)
DMF	dimethylformamide
DMSO	dimethyl sulphoxide
eq.	equivalent(s)
ESI	electrospray ionization (in MS)
Et	ethyl
GC/MS	gas chromatography-coupled mass spectrometry
sat.	saturated
h	hour(s)
HPLC	high-pressure high-performance liquid chromatography
HV	high vacuum
conc.	concentrated
LC/MS	liquid chromatography-coupled mass spectrometry
Me	methyl
min	minute(s)
MS	mass spectrometry
NMR	nuclear magnetic resonance spectroscopy
rac	racemic / racemate
R _f	retention factor (in thin layer chromatography on silica gel)
RT	room temperature
R _t	retention time (in HPLC)
SFC	supercritical fluid chromatography
THF	tetrahydrofuran
UV	ultraviolet spectrometry
v/v	volume to volume ratio (of a solution)

All x-ray diffractometry data were obtained with the following acquisition parameters:


	Diffractometer system	PANalytical XPERT-PRO
	Scan axis	Gonio
5	Anode material	Cu
	K-Alpha1 [Å]	1.54060
	K-Alpha2 [Å]	1.54443
	K-A2 / K-A1 ratio	0.50000
	Scan Mode:	Transmission
10	Scan type:	2theta:omega
	2theta figure:	$\pm 0.2^\circ$

All infrared spectroscopy data were obtained with the following acquisition parameters:

	Spectrometer:	Perkin Elmer Spectrum One with diamond ATR unit
15	Parameter:	32 scans
	Resolution:	2 cm ⁻¹

Example 1

2,2,3,3-Tetrafluoropropyl trifluoromethanesulphonate



5 Method A:

252.5 g (0.895 mol) of trifluoromethanesulphonic anhydride were heated to 40°C and, at this temperature, 130.0 g (0.984 mol) of 2,2,3,3-tetrafluoro-1-propanol were metered in while cooling. After the metered addition had ended, the reaction mixture was heated to 70°-75°C and stirred for 2 h. The mixture was cooled to 20°C and the reaction solution was used without further purification
10 in the reaction for Example 2.


Method B:

50.0 g (0.379 mol) of 2,2,3,3-tetrafluoro-1-propanol were cooled to 0°C and 106.8 g (0.379 mol) of trifluoromethanesulphonic anhydride were added dropwise at 0° - 4°C. Subsequently, the reaction mixture was stirred at 25°C for 2 h, heated to 70°-75°C and stirred for 2 h. The mixture was cooled
15 to 20°C and the reaction solution was distilled at 116° - 118°C. This gave 85.1 g (85.1 % of theory) of the title compound.

¹H NMR (400 MHz, CDCl₃): δ = 4.69 (t, *J*=11.86 Hz, 2 H) 5.54 - 6.23 (m, 1 H) ppm.

Example 2

4-(2,2,3,3-Tetrafluoropropyl)morpholine



20

Method A:

311.9 g (3.58 mol) of morpholine were dissolved in 290 ml of dichloromethane and cooled to -15°C. At -15° - 0°C, 371.4 g (max. 0.895 mol) of the reaction solution from Example 1 were added dropwise while cooling and then the mixture was stirred at 0° - 5°C for 30 min. The reaction

mixture was heated to 40°C and stirred for 4.5 h. After cooling to 20°C, 320 ml of water were added and the phases were separated. The organic phase was washed three times with 190 ml each time of water and concentrated on a rotary evaporator at 30°C/30 mbar. The residue (160.7 g) was distilled at 67° - 68°C/18 mbar. This gave 151.7 g (84.3 % of theory) of the title compound.


- 5 ¹H NMR (400 MHz, CDCl₃): δ = 2.53 - 2.70 (m, 4 H) 2.89 (tt, *J*=14.03, 1.74 Hz, 2 H) 3.61 - 3.78 (m, 4 H) 5.83 - 6.22 (m, 1 H) ppm.

Method B:

- 158.5 g (1.82 mol) of morpholine were cooled to 5°C. At 5° - 10°C, 189.5 g (max. 0.455 mol) of the reaction solution from Example 1 were added dropwise while cooling and then the mixture was stirred at 5° - 10°C for 30 min. The reaction mixture was heated to 40°C and stirred for 1 h. After cooling to 20°C, 160 ml of water and 160 ml of toluene were added and the phases were separated. The organic phase was washed with 160 ml of water and concentrated on a rotary evaporator at 50°C/50 mbar. The residue (81.0 g) was distilled at 67° - 68°C/18 mbar. This gave 77.0 g (84.1 % of theory) of the title compound.

15 **Example 3**

4-Methyl-4-(2,2,3,3-tetrafluoropropyl)morpholin-4-ium methanesulphonate



Method A:

- 143.7 g (1.31 mol) of methyl methanesulphonate were heated to 135°C and, at this temperature, 250.0 g (1.243 mol) of the compound from Example 2 were added dropwise. Subsequently, the mixture was stirred at 100°C for 22 h. The reaction mixture was cooled to 85°C and 375 ml of isopropanol were added. After cooling to 0° - 5°C, the mixture was stirred for a further 30 min and the product was filtered off with suction. The product was washed three times with 125 ml each time of isopropanol and dried in a vacuum drying cabinet at 45°C under a gentle nitrogen stream. This gave 336.8 g (87.1% of theory) of the title compound.


¹H NMR (400 MHz, D₂O): δ = 2.81 (s, 3 H) 3.55 (s, 3 H) 3.68 - 3.93 (m, 4 H) 4.01 - 4.24 (m, 4 H) 4.33 - 4.51 (m, 2 H) 6.13 - 6.48 (m, 1 H) ppm.

Method B:

20.0 g (181.3 mmol) of methyl methanesulphonate were heated to 135°C and, at this temperature, 35.1 g (172.7 mmol) of the compound from Example 2 were added dropwise. The mixture was stirred at 135°C for 3 h and then 40 ml of water were added. After cooling to 50°C, the aqueous solution of the title compound was used in the subsequent stage (see Example 4).

Example 4

4-Methyl-4-[2,3,3-trifluoroprop-1-en-1-yl]morpholin-4-ium methanesulphonate




16.9 g (189.9 mmol) of 45% sodium hydroxide solution were metered into the aqueous solution of the compound from Example 3, Method B (max. 172.7 mmol) at 50° - 55°C, and the mixture was stirred at 50°C for 1 h. The reaction mixture was cooled to 20°C and the precipitated salts were filtered off with suction and washed with 5 ml of water. The aqueous product solution (102.1 g; max. 172.7 mmol) was used in the subsequent stage (see Example 5).

For analytical purposes, a sample was concentrated and dried.

¹H NMR (400 MHz, D₂O): δ = 2.81 (s, 3 H) 3.59 (s, 3 H) 3.76 - 3.85 (m, 2 H) 3.97 - 4.09 (m, 4 H) 4.12 - 4.20 (m, 2 H) 6.39 - 6.69 (m, 1 H) 6.74 - 6.83 (m, 1 H) ppm.

Example 5

2-Fluoro-3-(morpholin-4-yl)acrylaldehyde



Method A:

An aqueous solution of the compound from Example 4 (max. 251.5 mmol) was heated to 75°C. Subsequently, 43.8 g (503 mmol) of morpholine and 76.3 g (755 mmol) of triethylamine were added dropwise. The mixture was stirred at 75°C for 2 h and cooled to 23°C, and 290 ml of

dichloromethane and 100 ml of triethylamine were added. The phases were separated, the aqueous phase was washed with a mixture of 290 ml of dichloromethane and 100 ml of triethylamine, and the combined organic phases were filtered, washed with 250 ml of sat. aqueous potassium carbonate solution and concentrated on a rotary evaporator at 40°C. 50 ml of toluene were added and the mixture was concentrated further. This gave 34.2 g (81.9% of theory) of the title compound.

Method B:

A mixture of 43.8 g (503 mmol) of morpholine and 76.3 g (755 mmol) of triethylamine was heated to 75°C and an aqueous solution of the compound from Example 4 (max. 251.5 mmol) was added dropwise within 25 min. Subsequently, the mixture was stirred at 75°C for 2 h and cooled to 23°C, and 290 ml of dichloromethane and 100 ml of triethylamine were added. The mixture was filtered, the phases were separated, the aqueous phase was washed with a mixture of 290 ml of dichloromethane and 100 ml of triethylamine, and the combined organic phases were washed with 250 ml of sat. aqueous potassium carbonate solution and concentrated on a rotary evaporator at 40°C. 50 ml of toluene were added and the mixture was concentrated further. This gave 35.3 g (83.4% of theory) of the title compound.

¹H NMR (500 MHz, CDCl₃): δ = 3.51 - 3.60 (m, 4 H) 3.72 - 3.83 (m, 4 H) 6.16 (d, *J*=27.1 Hz, 1 H) 8.59 (d, *J*=18.9 Hz, 1 H) ppm.


Method C:

A mixture of 30.2 g (345.3 mmol) of morpholine and 52.5 g (518.0 mmol) of triethylamine was heated to 75°C and the aqueous solution of the compound from Example 4, Method B (max. 172.7 mmol) was added dropwise at 75° - 80°C. The mixture was stirred under reflux for 2 h, cooled to 23°C and washed with 100 ml of dichloromethane. The aqueous phase was washed twice with a mixture of 100 ml of dichloromethane and 15 ml of triethylamine, and the combined organic phases were washed with 85 ml of sat. aqueous potassium carbonate solution and concentrated under reduced pressure at 45° - 50°C. 120 ml of toluene and 60 ml of toluene were distilled off. The suspension was stirred at room temperature overnight, and the product was filtered off with suction and dried in a vacuum drying cabinet at 50°C under a gentle nitrogen stream. This gave 19.2 g (68.3% of theory) of the title compound.

Example 6

Ethyl 5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate

- 41 -



Method A:

22.3 g (84.8 mmol) of ethyl 5-amino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate (preparation described for Example 20A in WO 00/06569) were initially charged in 59.5 ml of ethanol, and 11.0 ml (169.6 mmol) of methanesulphonic acid, 9.0 g (212.1 mmol) of lithium chloride and 15.0 g (84.8 mmol) of the compound from Example 5 were added at RT. The mixture was stirred at reflux temperature for 4.5 h. After cooling to room temperature, the product was filtered off with suction, washed twice with 4.5 ml of ethanol and stirred with 325 ml of water for 1 h. The solids were filtered off with suction, washed twice with 11.5 ml of water and dried in a vacuum drying cabinet at 50°C under a gentle nitrogen stream. This gave 21.8 g (81.0% of theory) of the title compound.

MS (ESIpos): $m/z = 318$ ($M+H$)⁺

¹H NMR (400 MHz, DMSO-d₆): $\delta = 1.37$ (t, 3H), 4.40 (q, 2H), 5.86 (s, 2H), 7.15 - 7.27 (m, 3H), 7.36 - 7.41 (m, 1H), 8.25 (d, 1H), 8.78 (s br., 1H) ppm.

Method B:


27.0 g (635.2 mmol) of lithium chloride and 42.2 g (254.1 mmol) of the compound from Example 5 were initially charged in 75 ml of ethanol and heated to reflux temperature. At this temperature, a solution of 66.9 g (254.1 mmol) of ethyl 5-amino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate (preparation described for Example 20A in WO 00/06569) and 33.0 ml (508.2 mmol) of methanesulphonic acid in 180 ml of ethanol were added within 10 min. The mixture was stirred at reflux temperature for 2 h, then 120 ml of isopropanol were added, the mixture was cooled to 62°C, 0.6 g of the title compound were used for seeding and the mixture was cooled to 5°C within 4 h. The product was filtered off with suction, stirred with 120 ml of isopropanol, filtered off with suction, washed with 180 ml of water, stirred with 300 ml of water for 0.5 h, filtered off with suction, washed with 300 ml of water and dried in a vacuum drying cabinet at 50°C under a gentle nitrogen stream. This gave 65.1 g (80.7% of theory) of the title compound.

Method C:

- 5.42 g (20.6 mmol) of ethyl 5-amino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate (preparation described for Example 20A in WO 00/06569) were initially charged in 20 ml of ethanol, and 1.5 g (41.1 mmol) of hydrogen chloride were introduced. This solution was metered into 3.42 g (20.6 mmol) of the compound from Example 5 in 50 ml of ethanol at reflux temperature within 10 min.
- 5 The mixture was stirred at reflux temperature for 2 h, then 10 ml of isopropanol were added and the mixture was cooled to 5°C. The product was filtered off with suction, washed with 10 ml of isopropanol and dried in a vacuum drying cabinet at 50°C under a gentle nitrogen stream. This gave 4.84 g (74.2% of theory) of the title compound.

Example 7

- 10 5-Fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide



- 10 ml of ethanol, 14.9 ml (441.2 mmol) of formamide and 3.6 g (66.2 mmol) of sodium methoxide solution in methanol (30%) were added to 7.0 g (22.1 mmol) of the compound obtained in Example 6. The reaction mixture was heated to 95° - 100°C and the low boilers were distilled off.
- 15 The mixture was stirred at 125°C for 1.5 h, 30 ml of water were added, and the mixture was cooled to room temperature and stirred for 1 h. The precipitated solids were filtered off with suction, washed three times with 8.5 ml each time of water and dried in a vacuum drying cabinet at 45°C under a gentle nitrogen stream. This gave 6.2 g (97.5% of theory) of the title compound.


MS (ESIpos): $m/z = 289$ ($M+H$)⁺

- 20 ¹H NMR (400 MHz, DMSO-d₆): $\delta = 5.87$ (s, 2H), 7.12 - 7.26 (m, 3H), 7.34 - 7.40 (m, 1H), 7.60 (s br., 1H), 7.87 (s br., 1H), 8.28 (dd, 1H), 8.72 (dd, 1H) ppm.

Example 8

5-Fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile

- 43 -




17.3 g (60.0 mmol) of the compound obtained in Example 7 were heated to 103° - 107°C in 40.5 ml of sulpholane and 5.4 ml of acetonitrile. Thereafter, 6.9 g (45.0 mmol) of phosphorus oxychloride were slowly added dropwise while stirring, the dropping funnel was rinsed with 2.8 ml of acetonitrile, then the mixture was stirred at 107°C for 1.5 h until conversion was complete (HPLC). Thereafter, the mixture was cooled to room temperature, and 2.8 ml of sulpholane/acetonitrile (5:1 vol/vol) and then 17.8 ml of water were added dropwise. The mixture was stirred for 0.5 h, a solution of 9.4 g of aqueous ammonia (28%) in 22.7 ml of water was added dropwise and the mixture was stirred for a further 2 h. The precipitated solids were filtered off with suction, washed three times with 20.5 ml each time of water and dried in a vacuum drying cabinet at 50°C under a gentle nitrogen stream. This gave 14.7 g (91.9% of theory) of the title compound.

MS (ESIpos): $m/z = 271$ (M+H)⁺

¹H NMR (400 MHz, DMSO-d₆): $\delta = 5.87$ (s, 2H), 7.17 - 7.42 (m, 4H), 8.52 (dd, 1H), 8.87 (dd, 1H) ppm.

15 Example 9

5-Fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide hydrochloride



406.0 g (1.50 mol) of the compound from Example 8 were suspended in 2.08 l of ethanol. Subsequently, 54.1 g (0.30 mol) of sodium methoxide in methanol (30%) were added and the mixture was stirred at room temperature overnight. 88.4 g (1.65 mol) of ammonium chloride were


added, and the mixture was heated to 65°C and stirred at 65°C for 3.5 h. The solvents were distilled off and the residue was stirred with 1.6 l of ethyl acetate overnight. The precipitated solids were filtered off with suction, washed twice with 140 ml each time of ethyl acetate and dried in a vacuum drying cabinet at 50°C under a gentle nitrogen stream. This gave 441.4 g (90.7% of theory) of the title compound.

MS (ESIpos): $m/z = 288$ (M+H)⁺

¹H NMR (400 MHz, DMSO-d₆): $\delta = 5.90$ (s, 2H), 7.15 - 7.20 (m, 1H), 7.22 - 7.28 (m, 1H), 7.29 - 7.35 (m, 1H), 7.36 - 7.43 (m, 1H), 8.48 (dd, 1H), 8.86 (dd, 1H), 9.35 (br. s, 3H) ppm.

Example 10

10 [(E)-phenyldiazenyl]malononitrile



Method A:

262 g of conc. hydrochloric acid (2.59 mol) and 117.5 ml of water were added dropwise at 0° - 5°C to 1525 ml of water and 117.5 g (1.26 mol) of aniline. Subsequently, a solution of 87.1 g (1.26 mol) of sodium nitrite in 222.5 ml of water was added dropwise within 1 h and rinsed in with 60 ml of water, and the mixture was stirred at 0° - 5°C for 15 min. Thereafter, at this temperature, a solution of 131.4 g (1.60 mol) of sodium acetate in 665 ml of water (19 ml) was added dropwise within 45 min and rinsed in with 60 ml of water, and a solution of 83.4 g (1.26 mol) of malononitrile in 233 ml of ethanol was added dropwise within 1 h. 68.5 ml of ethanol were used to rinse it in, and the mixture was stirred at 0° - 5°C for 2 h. The yellow solids were filtered off with suction and washed three times with 625 ml each time of water and with 488 ml of cold toluene. The still-moist residue was dissolved in 872 g of DMF. This gave 1117.0 g of DMF solution of the title compound.


25 Method B:

- 45 -

87.4 g of conc. hydrochloric acid (0.86 mol) and 39.5 ml of water were added dropwise at 0° - 5°C to 508.5 ml of water and 39.2 g (0.42 mol) of aniline. Subsequently, a solution of 29.0 g (0.42 mol) of sodium nitrite in 74.5 ml of water was added dropwise within 1 h and rinsed in with 20 ml of water, and the mixture was stirred at 0° - 5°C for 15 min. Thereafter, at this temperature, a solution of 43.8 g (0.54 mol) of sodium acetate in 221.5 ml of water was added dropwise within 45 min and rinsed in with 20 ml of water, and a solution of 27.8 g (0.42 mol) of malononitrile in 77.5 ml of ethanol was added dropwise within 1 h. 23 ml of ethanol were used to rinse it in, and the mixture was stirred at 0° - 5°C for 2 h. The yellow solids were filtered off with suction and washed three times with 208.5 ml each time of water and with 162.5 ml of cold toluene. 103.1 g of moist product were obtained. 13.8 g of the moist product were dissolved in 13.9 g of sulpholane. This gave 27.7 g of sulpholane solution of the title compound.

Example 11

2-[5-Fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-[(E)-phenyldiazenyl]pyrimidine-4,6-diamine

**Method A:**

448.2 g (1.38 mol) of the compound from Example 9 were suspended in 1059 ml of DMF. The mixture was heated to 85°C and 212 ml (1.52 mol) of triethylamine were added dropwise at this temperature. Subsequently, 1751 g of the DMF solution from Example 10 were added dropwise within 20 min and rinsed in with 490 ml of DMF, and the mixture was stirred at 100°C overnight. The reaction mixture was cooled to RT, 656 ml of water were added dropwise and the mixture was

stirred at RT for 0.5 h, then cooled to 0° - 5°C and stirred for a further 1 h. The solids were filtered off with suction, washed twice, each time with a solution of 1443 g of water and 236 g of methanol, and then washed with 586 ml of methanol, suction-dried and dried in a vacuum drying cabinet at 50°C under a gentle nitrogen stream. This gave 522.2 g (82.5% of theory) of the title compound.

- 5 ¹H NMR (400 MHz, DMSO-d₆): δ = 5.84 (s, 2 H) 7.14 - 7.28 (m, 3 H) 7.34 - 7.41 (m, 2 H) 7.46 - 7.52 (m, 2 H) 7.95 (br. s, 2 H) 8.02 (dd, 2 H) 8.50 (br. s, 2 H) 8.70 - 8.73 (m, 1 H) 9.02 - 9.06 (m, 1 H) ppm.

Method B:

- 30.0 g (92.7 mmol) of the compound from Example 9 were suspended in 72 ml of DMF. The mixture was heated to 100°C and a mixture of 14.2 ml (101.9 mmol) of triethylamine and 150 g of the DMF solution from Example 10 was added dropwise at this temperature within 30 min. 30 ml of DMF were used to rinse it in and the mixture was stirred at 100°C for 20 h. The reaction mixture was cooled to 95° - 90°C, 24 ml of water were added dropwise within 10 min, then the mixture was cooled to 0° - 5°C within 1.5 h and stirred for 1 h. The solids were filtered off with suction, washed with a solution of 60 g of water and 60 g of dimethylformamide, washed twice, each time with a solution of 50 g of water and 50 g of methanol, and then with 40 ml of methanol, suction-dried and dried in a vacuum drying cabinet at 50°C under a gentle nitrogen stream. This gave 35.5 g (83.7% of theory) of the title compound.


Method C:

- 11.7 g (36.0 mmol) of the compound from Example 9 were suspended in 15.6 ml of sulpholane. The mixture was heated to 100°C and a mixture of 5.5 ml (39.6 mmol) of triethylamine and 27.7 g of the sulpholane solution from Example 10 Method B was added dropwise at this temperature within 35 min. 2 ml of sulpholane were used to rinse it in and the mixture was stirred at 100°C for 2.5 h. The reaction mixture was cooled to 60°C, 90 ml of isopropanol were added dropwise, then the mixture was cooled to 0° - 5°C within 15 min and stirred for 2.5 h. The solids were filtered off with suction, washed three times, each time with 50 g of water and 24 ml of isopropanol, suction-dried and dried in a vacuum drying cabinet at 50°C under a gentle nitrogen stream. This gave 14.2 g (85.9% of theory) of the title compound.

Example 12

- 2-[5-Fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidine-4,5,6-triamine

- 47 -



Method A:

182.0 g (0.39 mol) of the compound from Example 11 were initially charged in 1.82 l of DMF and
5 then 4.2 g of palladium (5% on carbon, 50% water-moist) were added. Hydrogenation was effected
at 60°C and hydrogen pressure 60 bar while stirring overnight. The mixture was filtered through
kieselguhr and washed through with 150 ml of DMF and then with 150 ml of methanol, and
concentrated at 60° - 70°C down to a weight of 425 g of distillation residue. The residue was
heated to 75° - 80°C, 300 ml of methanol were added dropwise at this temperature and the mixture
10 was stirred for 15 min. The mixture was cooled to RT within 1 h, then 1290 ml of water were
added dropwise and the mixture was stirred overnight. The solids were filtered off with suction,
washed twice with 500 ml each time of water, suction-dried and dried in a vacuum drying cabinet
at 50°C under a gentle nitrogen stream. This gave 159.7 g of the title compound. The product has a
content of 73.7% by weight and 12.4% by weight of DMF (80.3% of theory) and was used thus in
15 the subsequent stage. According to the intensity of the water wash, the DMF content was in the
range of 10 – 17% by weight.

Method B:

25.0 g of the DMF-containing solids from Method A were suspended in 220 ml of water and
filtered with suction through a suction filter. The solids were washed four times on the suction filter
20 with 100 ml each time of water at 95°C, suction-dried and dried in a vacuum drying cabinet at
50°C under a gentle nitrogen stream. This gave 21.2 g of the DMF-free title compound.


MS (ESIpos): $m/z = 369$ (M+H)⁺

For analytical purposes, a sample was purified by means of silica gel filtration:

¹H NMR (400 MHz, DMSO-d₆): δ = 4.04 (br. s, 2 H) 5.75 (s, 2 H) 5.86 (br. s, 4 H) 7.10 - 7.26 (m, 3 H) 7.32 - 7.39 (m, 1 H) 8.61 - 8.64 (m, 1 H) 8.85 (dd, 1 H) ppm.

Example 13

5 Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate



Method A:

4.0 g (77.0% by weight, 8.36 mmol) of the compound from Example 12 in 37.9 ml of isopropanol were heated to 35°C and then 0.84 ml (10.87 mmol) of methyl chloroformate was added dropwise. The mixture was stirred at 35° - 40°C for 20 h and heated to 50°C, and 9.5 ml of methanol were added. Subsequently, 1.9 ml of triethylamine were added dropwise within 0.5 h and rinsed in with 1.3 ml of methanol, and the mixture was stirred at 50°C for 1 h. Thereafter, the reaction mixture was cooled to RT and stirred at RT for 1 h, and the solids were filtered off with suction, washed three times with 8 ml each time of ethanol, suction-dried and dried in a vacuum drying cabinet at 50°C under a gentle nitrogen stream. This gave 3.4 g of crude product. 3.0 g of the crude product were stirred in 8 ml of DMSO for 5 min, 13.0 ml of ethyl acetate and 50 mg of activated carbon were added, and the mixture was heated at reflux (84°C) for 15 min. The suspension was hot-filtered and the filter residue was washed with 1.9 ml of ethyl acetate¹⁾. 60 ml of ethyl acetate and 16 ml of ethanol were heated to 60°C, and the combined filtrates were added dropwise and stirred at 60°C for 1.5 h. The suspension was cooled to RT within 25 min, stirred for a further 1.5 h, cooled further to 0° - 5°C and stirred for a further 1 h. The solids were filtered off with suction, washed twice with 6.4 ml each time of ethyl acetate, suction-dried and dried in a vacuum drying cabinet at 50°C under a gentle nitrogen stream. This gave 2.2 g (70.0% of theory) of the title compound.

MS (ESIpos): $m/z = 427$ ($M+H$)⁺

¹H NMR (400 MHz, DMSO-d₆): $\delta = 3.62$ (br s, 3H), 5.79 (s, 2H), 6.22 (br s, 4H), 7.10 - 7.19 (m, 2H), 7.19 - 7.26 (m, 1H), 7.32 - 7.40 (m, 1H), 7.67 and 7.99 (2 br s, 1H), 8.66 (m, 1H), 8.89 (dd, 1H) ppm.

- 5 **1) According to the preparation process described, the di-dimethyl sulphoxide solvate is obtained at this point,** and this is characterized in Tables 2 and 4 by the reflections in the x-ray diffractogram and bands in the IR spectrum.

10 The di-dimethyl sulphoxide solvate of the compound of the formula (I) has the advantage of much better filterability than the substance in the prior art. Furthermore, the preparation process via the di-dimethyl sulphoxide solvate of the compound of the formula (I) leads to a very high purity of the compound of the formula (I).

Method B:

15 4.0 g (10.8 mmol) of the compound from Example 12 Method B in 37.9 ml of isopropanol were heated to 35°C and then 1.1 ml (14.1 mmol) of methyl chloroformate were added dropwise. The mixture was stirred at 35° - 40°C for 16.5 h and cooled to RT, and 2.1 ml of aqueous ammonia (28%) were added. Subsequently, 4.2 ml of water were added and the mixture was stirred for 2.5 h. The solids were filtered off with suction, washed twice with 5 ml each time of water, suction-dried and dried in a vacuum drying cabinet at 50°C under a gentle nitrogen stream. This gave 4.4 g of crude product.

20 Method C:

25 4.0 g (10.8 mmol) of the compound from Example 12 Method B in 37.9 ml of isopropanol were heated to 35°C and then 1.1 ml (14.1 mmol) of methyl chloroformate were added dropwise. The mixture was stirred at 35° - 40°C for 16.5 h, and 9.5 ml of methanol were added at 50°C. Subsequently, 2.42 ml of triethylamine were added dropwise within 20 min and rinsed in with 1.3 ml of methanol, and the mixture was stirred at 50°C for 1 h. Thereafter, the reaction mixture was cooled to RT and stirred at RT for 1 h, and the solids were filtered off with suction, washed three times with 8 ml each time of methanol, suction-dried and dried in a vacuum drying cabinet at 50°C under a gentle nitrogen stream. This gave 4.3 g of crude product.

Method D:

30 6.9 g of the crude product were stirred in 18.4 ml of DMSO for 5 min, 30.0 ml of ethyl acetate and 115 mg of activated carbon were added, and the mixture was heated at reflux (84°C) for 15 min. The suspension was hot-filtered and the filter residue was washed with 4.4 ml of ethyl acetate. 138

- 50 -

ml of ethyl acetate were heated to 50°C, and the combined filtrates were added dropwise and stirred at 45 - 50°C for 1 h. The suspension was cooled to 0° - 5°C within 1.5 h and stirred for a further 1 h. The solids were filtered off with suction, washed twice with 14.8 ml each time of ethyl acetate and suction-dried for 1 h. 6.4 g of the di-dimethyl sulphoxide solvate were obtained as a moist product¹⁾.

Method E:

2.0 g of the di-dimethyl sulphoxide solvate were stirred at reflux temperature in 40 ml of ethyl acetate and 11.1 ml of ethanol for 17 h, cooled to RT and stirred for a further 1 h. The solids were filtered off with suction, washed four times with 1.4 ml each time of ethyl acetate and dried in a vacuum drying cabinet at 50°C under a gentle nitrogen stream. This gave 1.4 g of the title compound present in polymorph I.

Method F:

0.5 g of the di-dimethyl sulphoxide solvate were stirred at reflux temperature in 12.5 ml of solvent for 17 h, cooled to RT and stirred for a further 1 h. The solids were filtered off with suction, washed with 2 ml of solvent and suction-dried for 30 min. This gave 0.3 g of the title compound present in polymorph I.

The following solvents were used:

- 1.) 9 ml of ethyl acetate/3.5 ml of ethanol/0.3 ml of water
- 2.) 12.5 ml of isopropanol
- 3.) 12.5 ml of isopropanol/0.3 ml of water
- 4.) 12.5 ml of methanol
- 5.) 12.5 ml of methanol/0.3 ml of water
- 6.) 12.5 ml of acetonitrile
- 7.) 12.5 ml of acetone
- 8.) 12.5 ml of tetrahydrofuran,
- 9.) 12.5 ml of methyl tert-butyl ether

Table 1 indicates the reflections of the x-ray diffractogram. Table 3 shows the bands of the IR spectrum.

The compound (I) in crystalline polymorph I is notable for higher stability and more particularly for the fact that it is stable in the micronization process and hence no conversion and recrystallization takes place.

- 5 The compound of the formula (I) can be prepared by processes described above. This affords the compound of the formula (I) in a crystal polymorph referred to hereinafter as polymorph I. Polymorph I has a melting point of 257°C and a characteristic x-ray diffractogram featuring the reflections (2 theta) 5.9, 6.9, 16.2, 16.5, 24.1 and 24.7, and a characteristic IR spectrum featuring the band maxima (in cm⁻¹) 1707, 1633, 1566, 1475, 1255 and 1223 (Tables 1 and 3, Figures 1 and 5).
- 10 Surprisingly, four further polymorphs, a monohydrate, a dihydrate, a DMF/water solvate and a dimethyl sulfoxide solvate, and also a triacetic acid solvate of the compound of the formula (I) were found. The compound of the formula (I) in polymorph II melts at approx. 253°C; the compound of the formula (I) in polymorph III has a melting point of approx. 127°C. Polymorph IV of the compound of the formula I melts at a temperature of 246°C, while polymorph V has a melting point of 234°C. The
- 15 monohydrate contains approx. 4.1% water, the dihydrate contains 7.8% water, the DMF/water solvate contains 13.6% dimethylformamide and 0.9 % water, the di-DMSO solvate contains 26.8% dimethyl sulphoxide and the triacetic acid solvate contains 29.7% acetate. Each of the crystalline forms mentioned has a characteristic x-ray diffractogram and IR spectrum (Tables 2 and 3, Figures 1 - 4, 6 - 14).

Table 1: X-ray diffractometry for polymorphs I to V

Reflections				
Polymorph I [2 theta]	Polymorph II [2 theta]	Polymorph III [2 theta]	Polymorph IV [2 theta]	Polymorph V [2 theta]
5.9	4.9	6.2	6.2	3.2
6.9	7.3	6.8	8.7	5.1
8.3	9.7	8.7	12.4	5.4
10.4	9.9	9.8	15.8	6.4
10.5	10.8	12.4	18.1	6.6
11.3	14.3	15.8	18.6	10.2
11.6	14.9	17.5	19.2	10.7
11.9	15.6	18.1	19.6	11.8
12.2	16.5	18.6	20.2	12.8
14.5	18.1	19.1	20.9	13.2
14.7	18.3	19.6	21.8	15.2
15.1	19.6	20.1	22.3	15.5
16.2	21.0	21.0	23.1	15.7
16.5	21.8	21.9	23.7	16.3
20.0	22.4	22.8	24.2	17.0
21.9	23.1	23.7	26.0	17.7
22.7	23.7	24.5	26.5	17.9
23.5	27.1	25.3	29.2	19.6
24.1	28.1	25.7	31.3	22.1
24.7		26.8	33.8	22.8
25.4		27.5		23.5
25.7		28.2		24.4
26.6		29.6		26.3
28.0		30.9		27.9
30.2		31.3		28.3
		31.6		29.3
		32.8		30.3
		33.8		
		34.6		

Table 2: X-ray diffractometry for polymorph hydrates and solvates

Reflections				
Monohydrate [2 theta]	Dihydrate [2 theta]	DMF/water solvate [2 theta]	di-DMSO solvate [2 theta]	Acetic acid solvate [2 theta]
6.0	5.9	8.2	6.9	5.3
8.5	7.9	9.2	11.0	7.2
9.6	8.7	9.7	12.0	9.3
12.1	9.0	11.9	13.8	10.0
13.6	11.8	12.5	14.1	10.7
15.5	13.7	12.7	15.7	11.0
17.3	14.7	13.3	16.1	11.6
18.2	15.8	14.1	16.2	11.9
19.3	16.4	15.6	16.6	12.5
19.7	18.1	16.0	17.1	14.1
20.2	19.3	16.5	17.7	14.4
20.9	19.8	16.8	17.8	14.8
21.5	20.6	17.6	18.8	16.6
22.2	21.7	18.3	19.9	18.0
23.5	21.7	19.3	20.3	18.8
24.1	22.5	19.4	20.7	19.2
25.7	22.7	19.6	21.3	19.4
26.8	22.9	19.8	21.7	19.6
27.5	23.4	20.0	21.9	19.7
29.4	23.7	20.5	22.4	20.1
30.8	24.9	20.6	22.8	20.4
32.2	25.5	20.7	23.6	21.0
	26.0	21.0	24.1	21.6
	26.8	21.8	24.4	22.9
	27.1	22.2	25.2	23.5
	27.8	22.4	25.5	24.1
	28.9	22.8	25.9	24.4
	30.7	23.1	26.6	24.8
	31.3	23.6	26.9	25.5
	32.0	23.9	28.9	26.5

- 54 -

		24.8	29.9	26.8
		25.2	30.9	27.7
		25.6	33.2	31.5
		25.8	33.4	
		26.1	33.9	
		26.7		
		26.8		
		27.2		
		27.6		
		28.1		
		28.4		
		28.6		
		29.4		
		29.7		
		30.3		
		30.6		
		31.4		
		31.5		
		31.7		
		32.1		
		32.4		
		32.6		
		32.7		
		34.1		
		34.3		
		34.7		
		35.6		
		35.9		
		36.6		

Table 3: IR spectra of polymorphs I to V

Band maxima				
Polymorph I [cm ⁻¹]	Polymorph II [cm ⁻¹]	Polymorph III [cm ⁻¹]	Polymorph IV [cm ⁻¹]	Polymorph V [cm ⁻¹]
690	691	697	698	691
744	752	744	752	745
761	771	753	773	759
774	779	773	809	773
810	810	808	833	809
845	848	835	873	847
872	871	873	911	873
899	903	913	936	896
960	933	935	955	912
1059	958	954	1058	933
1072	1031	1034	1077	961
1112	1067	1059	1104	1033
1157	1082	1075	1161	1057
1208	1111	1103	1207	1083
1223	1202	1161	1225	1112
1255	1223	1206	1237	1152
1305	1249		1256	1207
1319	1264	1237	1277	1224
1353	1305	1253	1317	1255
1370	1349	1278	1356	1305
1435	1368	1319	1370	1318
1475	1436	1355	1425	1351
1566	1456	1370	1457	1371
1620	1480	1424	1472	1436
1633	1566	1437	1490	1478
1707	1620	1458	1496	1567
2956	1704	1476	1573	1628
3130	2953	1489	1585	1707
3277	3132	1570	1618	2956
3332	3278	1587	1691	3143

3385	3361	1619	3208	3277
3490	3488	1695	3290	3319
	3503	3203	3376	3452
		3315	3482	3492
		3379		
		3479		

Table 4: IR spectra of the hydrates and solvates

Band maxima				
Monohydrate [cm ⁻¹]	Dihydrate [cm ⁻¹]	DMF/water solvate [cm ⁻¹]	di-DMSO solvate [cm ⁻¹]	Acetic acid solvate [cm ⁻¹]
696	745	662	713	709
743	752	724	762	739
761	760	745	778	762
774	774	771	811	777
810	809	812	873	801
834	835	846	902	835
873	874	867	953	872
912	913	896	1017	918
953	937	932	1041	941
1066	955	965	1078	955
1079	1032	1054	1111	1059
1104	1061	1072	1164	1099
1160	1080	1096	1210	1113
1176	1105	1117	1234	1167
1205	1160	1160	1281	1236
1222	1174	1209	1321	1252
1236	1206	1243	1364	1357
1249	1224	1304	1432	1423
1278	1236	1356	1457	1456
1356	1259	1389	1481	1492
1370	1309	1434	1521	1577
1423	1356	1481	1569	1601
1456	1371	1561	1628	1643

1474	1422	1624	1720	1702
1491	1473	1654	3144	3342
1575	1497	1729	3288	
1620	1575	3159	3423	
1669	1622	3404		
3294	1688	3498		
3331	3195			
3479	3304			
	3472			
	3676			

Figure 1: IR spectrum of the compound of the formula (I) in polymorphs I, II and III

Figure 2: IR spectrum of the compound of the formula (I) in polymorphs IV, V and as the
5 triacetic acid solvate

Figure 3: IR spectrum of the compound of the formula (I) as the di-DMSO solvate,
DMF/water solvate and monohydrate

Figure 4: IR spectrum of the compound of the formula (I) as the dihydrate

Figure 5: X-ray diffractogram of the compound of the formula (I) in polymorph I

10 Figure 6: X-ray diffractogram of the compound of the formula (I) in polymorph II

Figure 7: X-ray diffractogram of the compound of the formula (I) in polymorph III

Figure 8: X-ray diffractogram of the compound of the formula (I) in polymorph IV

Figure 9: X-ray diffractogram of the compound of the formula (I) in polymorph V

15 Figure 10: X-ray diffractogram of the compound of the formula (I) as the triacetic acid
solvate

Figure 11: X-ray diffractogram of the compound of the formula (I) as the di-DMSO solvate

Figure 12: X-ray diffractogram of the compound of the formula (I) as the DMF-water solvate

Figure 13: X-ray diffractogram of the compound of the formula (I) as the monohydrate

20 Figure 14: X-ray diffractogram of the compound of the formula (I) as the dihydrate


Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

- 5 The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.


2012342547 03 Jul 2017

The claims defining the invention are as follows:


1. Process for preparing a compound of the formula (VI)



wherein the compound of the formula (V)



is prepared by reaction of an ester of the formula (IVa)




in which

T¹ is (C₁-C₄)-alkyl,

with formamide.


2. Process according to Claim 1, wherein an ester of the formula (IVa) is prepared by cyclizing the 5-aminopyrazole derivative (IIa)




in which

T^1 is (C₁-C₄)-alkyl,


in the presence of an alkali metal salt and an acid with an aldehyde of the formula (III)




in which R¹ and R² are each independently methyl, ethyl, isopropyl, phenyl or, together with the nitrogen atom to which they are bonded, are




3. Process according to Claim 2, wherein the aldehyde used in the cyclization reaction is the compound of the formula (IIIa)



4. Process for preparing a compound of the formula (I)




wherein a compound of the formula (VI)



is used,

wherein the compound of formula (VI) is prepared by a process as defined in any one of Claims 1 to 3 and the resulting compound of the formula (I) is optionally converted, with one or more appropriate (i) solvents and/or (ii) acids or bases, to a solvate, salt or solvate of a salt thereof.


5. Process for preparing a compound of the formula (I), wherein a compound of the formula (VI)



is used,

wherein the compound of formula (VI) is prepared by a process as defined in any one of Claims 1 to 3 and the resulting compound of the formula (I) is optionally converted, with one or more appropriate (i) solvents and/or (ii) acids or bases, to a solvate, salt or solvate of a salt thereof.

6. Process for preparing a compound of the formula (I), wherein a compound of the formula (VI)




is used,


wherein the compound of formula (VI) is prepared by a process as defined in any one of Claims 1 to 3 and the resulting compound of the formula (I) is optionally converted, with one or more appropriate (i) solvents and/or (ii) acids or bases, to a solvate, salt or solvate of a salt thereof.

7. Process for preparing a compound of the formula (I), wherein a compound of the formula (VI) is used, this being prepared according to any one of Claims 1 to 3, by converting the compound of the formula (VI) to the compound of the formula (VII)


- 62 -




subsequently reacting the compound of the formula (VII) in an inert solvent in the presence of a suitable base with a compound of the formula (VIIIa)



to give the compound of the formula (VIII)




and then reducing the compound of the formula (VIII) in an inert solvent in the presence of a suitable reducing agent to give the compound (IX)




and thereafter reacting the compound of the formula (IX) with methyl chloroformate or with dimethyl dicarbonate in the presence of a suitable base, with or without solvent, to give the compound of the formula (I), and optionally converting the resulting compound of the formula (I) with one or more appropriate (i) solvents and/or (ii) acids or bases, to a solvate, salt or solvate of a salt thereof.

8. Compound of the formula (I) in crystalline form of polymorph I



wherein the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 5.9, 6.9 and 22.7.


9. Compound according to Claim 8, wherein the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 5.9, 6.9, 16.2, 16.5, 24.1, 22.7 and 24.7.
10. Compound of the formula (I) in crystalline form of polymorph I



wherein the IR spectrum of the compound exhibits band maxima at 1707, 1633 and 1475 cm^{-1} .


11. Compound according to Claim 10, wherein the IR spectrum of the compound exhibits band maxima at 1707, 1633, 1566, 1475, 1255 and 1223 cm^{-1} .
12. Process for preparing a compound of the formula (I) in crystalline form of polymorph I, wherein the compound of the formula (I), present in one or more polymorphs or as a solvate in an inert solvent, is stirred at a temperature in the range of 20°C - 120°C and the compound of the formula (I) is isolated as crystalline polymorph I.
13. Medicament comprising a compound according to any one of Claims 8 to 11 and no greater proportions of any other form of the compound of the formula (I).
14. Medicament comprising a compound according to any one of Claims 8 to 11 in more than 90 per cent by weight based on the total amount of the compound of the formula (I) present.
15. Use of a compound according to any one of Claims 8 to 11 in the manufacture of a medicament for the treatment of a cardiovascular disorder.
16. Method for the treatment of a cardiovascular disorder, the method comprising administering an effective amount of a compound according to any one of Claims 8 to 11.

17. Crystalline substance compound of the formula (I) in the form of the di-dimethyl sulphoxide solvate,



wherein the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 18.8, 20.3 and 21.7.

18. Compound according to Claim 17, wherein the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 12.0, 16.6, 17.8, 18.8, 20.3 and 21.7.
19. Crystalline substance compound of the formula (I) in the form of the di-dimethyl sulphoxide solvate,




wherein the IR spectrum of the compound exhibits band maxima at 1720, 1628 and 1481 cm^{-1} .


20. Compound according to Claim 19, wherein the IR spectrum of the compound exhibits band maxima at 1720, 1628, 1481, 1234, 1041 and 1017 cm^{-1} .
21. Process for preparing a compound of the formula (I) as the di-dimethyl sulphoxide solvate in crystalline form, wherein the compound of the formula (I), present in one or more polymorphs or as a solvate in dimethyl sulphoxide, or a mixture of dimethyl sulphoxide and an inert solvent, is stirred at a temperature in the range of 20 - 120°C and the di-dimethyl sulphoxide solvate is isolated.

2012342547 25 Jul 2017


Figure 1: IR spectra of the compound of the formula I in polymorph I, II and III



Polymorph I




5 Polymorph II




Polymorph III

Figure 2: IR spectra of the compound of the formula I in polymorph IV, V and of the triacetic acid solvate




Polymorph IV




5

Polymorph V




Triacetic acid solvate

Figure 3: IR spectra of the compound of the formula I as the di-DMSO solvate, DMF/water solvate and the monohydrate




Di-DMSO solvate




5

DMF/water solvate



Monohydrate

Figure 4: IR spectra of the compound of the formula I as the dihydrate



Dihydrate

Figure 5: X-ray powder diffractograms of the compound of the formula I in polymorph I




Figure 6: X-ray powder diffractograms of the compound of the formula I in polymorph II




Figure 7: X-ray powder diffractograms of the compound of the formula I in polymorph III






Figure 8: X-ray powder diffractograms of the compound I in polymorph IV




9/14

Figure 9: X-ray powder diffractograms of the compound I in polymorph V




10/14

Figure 10: X-ray powder diffractograms of the compound of the formula I as the triacetic acid solvate



11/14

Figure 11: X-ray powder diffractograms of the compound of the formula I as the di-DMSO solvate



12/14

Figure 12: X-ray powder diffractograms of the compound of the formula I as the DMF-water solvate





Figure 13: X-ray powder diffractograms of the compound of the formula I as the monohydrate



14/14

Figure 14: X-ray powder diffractograms of the compound I as the dihydrate

